• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular

  • A Multi-centre, Double-blind, Randomised, Placebo-controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure.

Disease
atrial fibrillation
Drug Name
AZD1305
Generic Name
AZD1305
Sponsor
AstraZeneca
Drug Status
Discontinued
Phase
II
Start Date
Jan 23, 2008
Study Name
D3190C00005
Study Id
D3190C00005
ClinicalTrials.gov ID
NCT00616629
Recruiting Status
Closed
Protocol Status
Not Available
Report
Apr 27, 2009
  • D3190C00005.pdf (522 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013